Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 98 articles:
HTML format
Text format



Single Articles


    December 2017
  1. GUIHOT A, Marcelin AG, Massiani MA, Samri A, et al
    Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
    Ann Oncol. 2017 Dec 1. pii: 4677259. doi: 10.1093.
    PubMed     Text format    


    November 2017
  2. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    Nivolumab in non-small cell lung cancer with EGFR mutation.
    Ann Oncol. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format    


  3. EK L, Gezelius E, Bergman B, Bendahl PO, et al
    Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  4. OTSUBO K, Seki N, Nakanishi Y, Okamoto I, et al
    Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


  5. ULAHANNAN D, Khalifa J, Faivre-Finn C, Lee SM, et al
    Emerging treatment paradigms in brain metastasis in non-small cell lung cancer: an overview of the current landscape and challenges ahead.
    Ann Oncol. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. SORIA JC, Fulop A, Maciel C, Fischer JR, et al
    SELECT-2: a Phase II, double-blind, randomised, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment for patients with advanced or metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Oct 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. MARTINEZ-MARTI A, Felip E, Matito J, Mereu E, et al
    Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Ann Oncol. 2017;28:2451-2457.
    PubMed     Text format     Abstract available


  8. CALVO E, Moreno V, Flynn M, Holgado E, et al
    Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Ann Oncol. 2017;28:2559-2566.
    PubMed     Text format     Abstract available


    September 2017
  9. NOKIHARA H, Lu S, Mok TSK, Nakagawa K, et al
    Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. WEBER S, Wolkewitz M, Schumacher M
    Analyzing the impact of Depth of Response on Survival in patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format    


  11. ARGIRIS A, Lee JW, Stevenson J, Sulecki MG, et al
    Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. KATAKAMI N, Felip E, Spigel DR, Kim JH, et al
    A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
    Ann Oncol. 2017;28:2241-2247.
    PubMed     Text format     Abstract available


  13. ITO M, Fujiwara S, Fujimoto D, Mori R, et al
    Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.
    Ann Oncol. 2017;28:2318-2319.
    PubMed     Text format    


    August 2017
  14. SAAD ED, Buyse M
    Editorial on "Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy".
    Ann Oncol. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format    


  15. KOLLER M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, et al
    An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. MAENO K, Fukuda S, Oguri T, Niimi A, et al
    Nivolumab-induced asthma in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format    


  17. MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. CURIONI-FONTECEDRO A, Ickenberg C, Franzen D, Rogler G, et al
    Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Ann Oncol. 2017;28:2040-2041.
    PubMed     Text format    


    July 2017
  19. LEDUC C, Merlio JP, Besse B, Blons H, et al
    Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
    Ann Oncol. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. HENTRICH M, Schipek-Voigt K, Jager H, Schulz S, et al
    Nivolumab in HIV-related non-small-cell lung cancer.
    Ann Oncol. 2017 Jul 6. doi: 10.1093.
    PubMed     Text format    



  21. Appendix 8: Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    



  22. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    


  23. POSTMUS PE, Kerr KM, Oudkerk M, Senan S, et al
    Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2017;28.
    PubMed     Text format    


    June 2017
  24. TOMITA Y, Sueta D, Kakiuchi Y, Saeki S, et al
    Acute Coronary Syndrome as a Possible Immune-Related Adverse Event in a Lung Cancer Patient Achieving a Complete Response to Anti-PD-1 Immune Checkpoint Antibody.
    Ann Oncol. 2017 Jun 23. doi: 10.1093.
    PubMed     Text format    


  25. LINDSAY CR, Faugeroux V, Michiels S, Pailler E, et al
    A Prospective Examination of Circulating Tumor Cell Profiles in Non-Small Cell Lung Cancer Molecular Subgroups.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. DEVARAKONDA S, Govindan R
    TRAC(ERx)-ing Lung Cancer Evolution.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format    


  27. SANMAMED MF, Perez-Gracia JL, Schalper KA, Fusco JP, et al
    Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients.
    Ann Oncol. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  28. CHRISTOPOULOS P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, et al
    Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
    Ann Oncol. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. CURROW D, Temel JS, Abernethy A, Milanowski J, et al
    ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia.
    Ann Oncol. 2017 May 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
    Ann Oncol. 2017;28:1084-1089.
    PubMed     Text format     Abstract available


  31. ZHANG L, Ye Y, Tu H, Hildebrandt MA, et al
    MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.
    Ann Oncol. 2017;28:1124-1129.
    PubMed     Text format     Abstract available


    April 2017
  32. DHILLON HM, Bell ML, van der Ploeg HP, Turner JD, et al
    Impact of Physical Activity on Fatigue and Quality of Life in People with Advanced Lung Cancer: a Randomised Controlled Trial.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. HARATANI K, Hayashi H, Tanaka T, Kaneda H, et al
    Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. SEO S, Woo CG, Lee DH, Choi J, et al
    The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small cell lung cancer.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format    


  35. FERRONIKA P, van den Bos H, Taudt A, Spierings DCJ, et al
    Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small cell lung cancer patient.
    Ann Oncol. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format    


  36. ZHANG Y, Zhang L, Li R, Chang DW, et al
    Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.
    Ann Oncol. 2017 Apr 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. REMON J, Caramella C, Jovelet C, Lacroix L, et al
    Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
    Ann Oncol. 2017;28:784-790.
    PubMed     Text format     Abstract available


    March 2017
  38. KATAOKA Y, Ebi N, Fujimoto D, Hara S, et al
    Prior radiotherapy does not predict nivolumab response in non-small cell lung cancer: a retrospective cohort study.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format    


    February 2017
  39. ZOU T, Awad MM
    More valuable than platinum: first-line pembrolizumab in advanced stage non-small cell lung cancer.
    Ann Oncol. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format    


  40. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomised trial.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2017, with focus on lung cancer.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. TANG H, Wang S, Xiao G, Schiller J, et al
    Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
    Ann Oncol. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  43. ZHANG L, Ye Y, Tu H, Hildebrandt MA, et al
    MicroRNA Related Genetic Variants in Iron Regulatory Genes, Dietary Iron Intake, MicroRNAs and Lung Cancer Risk.
    Ann Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  44. PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  45. HUI R, Garon EB, Goldman JW, Leighl NB, et al
    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  46. PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Ann Oncol. 2017;28:270-277.
    PubMed     Text format     Abstract available


  47. YOSHIOKA H, Katakami N, Okamoto H, Iwamoto Y, et al
    A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
    Ann Oncol. 2017;28:285-291.
    PubMed     Text format     Abstract available


  48. REMON J, Soria JC
    Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Ann Oncol. 2017;28:196-198.
    PubMed     Text format    


    January 2017
  49. TSAO MS, Le Teuff G, Shepherd FA, Landais C, et al
    PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
    Ann Oncol. 2017 Jan 30. pii: mdx003. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. LIANG J, Bi N, Wu S, Chen M, et al
    Etoposide and Cisplatin vs Paclitaxel and Carboplatin With Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Trial.
    Ann Oncol. 2017 Jan 30. pii: mdx009. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. KADARA H, Choi M, Zhang J, Parra ER, et al
    Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Ann Oncol. 2017;28:75-82.
    PubMed     Text format     Abstract available


    December 2016
  52. WOO CG, Seo S, Kim SW, Jang SJ, et al
    Differential protein stability and clinical responses of EML4-ALKfusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Ann Oncol. 2016 Dec 29. pii: mdw693. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. OSORIO JC, Ni A, Chaft JE, Pollina R, et al
    Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw640. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2016
  54. BELANI CP, Chakraborty B, Modi R, Khamar B, et al
    A Randomized Trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  55. LACOUTURE ME
    reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccar
    Ann Oncol. 2016;27:2138-2139.
    PubMed     Text format    


  56. LEE SH, Lee JK, Ahn MJ, Kim DW, et al
    Vandetanib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring RET Rearrangement: A Phase II Clinical Trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  57. REMON J, Soria JC
    Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Ann Oncol. 2016 Oct 25. doi: 10.1093.
    PubMed     Text format    


  58. KANDA S, Goto K, Shiraishi H, Kubo E, et al
    Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  59. NISHIKAWA S, Tambo Y, Ninomiya H, Oguri T, et al
    A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format    


    September 2016
  60. DICKHOFF C, Hartemink KJ, Kooij J, van de Ven PM, et al
    Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?
    Ann Oncol. 2016.
    PubMed     Text format    


    August 2016
  61. DE BOER P, Dahele MR, Senan S
    Is radical chemo-radiotherapy appropriate in patients with stage IV non-small-cell lung cancer due to cervical lymph node metastases?
    Ann Oncol. 2016.
    PubMed     Text format    


  62. KINOSHITA T, Muramatsu R, Fujita T, Nagumo H, et al
    Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  63. OLAUSSEN KA, Postel-Vinay S
    Predictors of chemotherapy efficacy in Non-Small Cell Lung Cancer : a challenging landscape.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  64. CECCARELLI G, Schietroma I, Corano Scheri G, d'Ettorre G, et al
    Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with Advanced Non-Small-Cell Lung Cancer enrolled in ARCHER-1042 trial.
    Ann Oncol. 2016.
    PubMed     Text format    


  65. JOERGER M, von Pawel J, Kraff S, Fischer JR, et al
    Open-label, randomised study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  66. MANSFIELD AS, Aubry MC, Moser J, Harrington S, et al
    Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  67. BROWER JV, Amini A, Chen S, Hullett CR, et al
    Improved survival with dose escalated radiotherapy in Stage III non-small cell lung cancer: Analysis of the National Cancer Data Base.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  68. DE RUYSSCHER D, Lueza B, Le Pechoux C, Johnson DH, et al
    Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  69. FRUH M, Ris HB, Xyrafas A, Peters S, et al
    Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
    Ann Oncol. 2016.
    PubMed     Text format    


  70. GARRIDO P, Palacios J
    Necitumumab in Squamous Non Small Cell Lung Cancer: How to move forward?
    Ann Oncol. 2016.
    PubMed     Text format    


  71. LACOUTURE ME, Keefe DM, Sonis S, Jatoi A, et al
    A Phase II Study (ARCHER 1042) to Evaluate Prophylactic Treatment of Dacomitinib-induced Dermatologic and Gastrointestinal Adverse Events in Advanced Non-Small-Cell Lung Cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  72. KREBBER AM, Jansen F, Witte BI, Cuijpers P, et al
    Stepped Care Targeting Psychological Distress in Head and Neck Cancer and Lung Cancer Patients: a Randomized Controlled Trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  73. RAMALINGAM SS, O'Byrne K, Boyer M, Mok T, et al
    Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ann Oncol. 2016.
    PubMed     Text format    


  74. PATEL JD, Pereira JR, Chen J, Liu J, et al
    Relationship between Efficacy Outcomes and Weight Gain during Treatment of Advanced, Nonsquamous, Non-small Cell Lung Cancer Patients.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  75. PAZ-ARES L, Socinski MA, Shahidi J, Hozak RR, et al
    Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients wit
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  76. CHATTERJEE M, Turner DC, Felip E, Lena H, et al
    Systematic evaluation of pembrolizumab dosing in patients with advanced non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  77. VAN KRUIJSDIJK RC, Visseren FL, Boni L, Groen HJ, et al
    Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small cell lung cancer: treating the right patients based on individualized treatment effect prediction.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  78. KANAI O, Fujita K, Okamura M, Nakatani K, et al
    Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.
    Ann Oncol. 2016.
    PubMed     Text format    


  79. MORROW CJ, Trapani F, Metcalf RL, Bertolini G, et al
    Tumourigenic Non-Small Cell Lung Cancer Mesenchymal Circulating Tumour Cells - A Clinical Case Study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  80. CHERNY NI, Kloke M, Cervantes A, Pentheroudakis G, et al
    Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al.
    Ann Oncol. 2016;27:550-1.
    PubMed     Text format    


    February 2016
  81. BRACARDA S
    More colors to the palette.
    Ann Oncol. 2016;27:363.
    PubMed     Text format    


    January 2016
  82. JAMAL-HANJANI M, Wilson GA, Horswell S, Mitter R, et al
    Detection of Ubiquitous and Heterogeneous Mutations in Cell-Free DNA from Patients with Early-Stage Non-Small-Cell Lung Cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  83. TAKEGAWA N, Hayashi H, Iizuka N, Takahama T, et al
    Transformation of ALK rearrangement-positive adenocarcinoma to small cell lung cancer in association with acquired resistance to alectinib.
    Ann Oncol. 2016.
    PubMed     Text format    


  84. CARTER CA, Rajan A, Keen C, Szabo E, et al
    Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  85. DOWLATI A, Lipka MB, McColl K, Dabir S, et al
    Clinical Correlation of Extensive-Stage Small Cell Lung Cancer Genomics.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  86. TAKEDA M, Sakai K, Okamoto K, Hayashi H, et al
    Genome sequencing for non-small cell lung cancer identifies a basis for nintedanib sensitivity.
    Ann Oncol. 2016.
    PubMed     Text format    


  87. RAMALINGAM SS, O'Byrne K, Boyer M, Mok T, et al
    Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  88. JOHNSON MJ, Currow DC
    How much evidence isn't in evidence-based guidelines?
    Ann Oncol. 2016;27:205.
    PubMed     Text format    


  89. BASSO U, Maruzzo M
    More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis.
    Ann Oncol. 2016;27:202-3.
    PubMed     Text format    


    December 2015
  90. SCHILD SE, Vokes EE
    Pathways to improving combined modality therapy for stage III non-small cell lung cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  91. TREASURE T, Macbeth F
    The GILDA trial finds no survival benefit from intensified screening after primary resection of colorectal cancer: the PulMiCC trial tests the survival benefit of pulmonary metastasectomy for detected asymptomatic lung metastases.
    Ann Oncol. 2015.
    PubMed     Text format    


  92. BEAU-FALLER M, Cadranel J
    Reply to the letter to the editor "Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients" by Krawczyk et al.
    Ann Oncol. 2015.
    PubMed     Text format    


  93. SCHULER M, Yang JC, Park K, Kim JH, et al
    Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  94. MAZIERES J, Barlesi F, Filleron T, Besse B, et al
    Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: Results from the European EUHER2 cohort.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  95. SWANTON C, Boffetta P, Peston R, Soria JC, et al
    Environmental Emissions, Public Health and Lung Cancer Risk.
    Ann Oncol. 2015.
    PubMed     Text format    


  96. KRAWCZYK P, Reszka K, Ramlau R, Powrozek T, et al
    Prevalence of rare EGFR gene mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients.
    Ann Oncol. 2015.
    PubMed     Text format    


  97. DONNEM T, Kilvaer TK, Andersen S, Richardsen E, et al
    Strategies for clinical implementation of TNM-immunoscore in resected non-small cell lung cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  98. PIETRANTONIO F, Cremolini C
    Authors' Response: how to address the issue of "rare" mutations for improving colorectal cancer patients' care.
    Ann Oncol. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: